.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,027,714

« Back to Dashboard
Patent 6,027,714 protects PULMICORT FLEXHALER and is included in one NDA.

This patent has forty-two patent family members in thirty-two countries.

Summary for Patent: 6,027,714

Title: Formulation for inhalation
Abstract:A dry powder composition comprising budesonide and a carrier substance, both of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml is useful in the treatment of respiratory disorders.
Inventor(s): Trofast; Jan (Lund, SE)
Assignee: Astra Aktiebolag (SE)
Application Number:09/004,894
Patent Claim Types:
see list of patent claims
Composition; Use; Process;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 28th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca
PULMICORT FLEXHALER
budesonide
POWDER, METERED;INHALATION021949-001Jul 12, 2006RXNo6,027,714► subscribeY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
Astrazeneca
PULMICORT FLEXHALER
budesonide
POWDER, METERED;INHALATION021949-002Jul 12, 2006RXYes6,027,714► subscribeY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,027,714

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9700133Jan 20, 1997

International Patent Family for Patent: 6,027,714

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria389390► subscribe
Australia5785798► subscribe
Australia726916► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc